الفهرس 
Hepatocellular CarcinomaOnly 14 pages are availabe for public view
 |  | from | 139 |  |  |
| | | from | 139 | | |
Abstract
Abstract: Cirrhosis is the end result of chronic liver damage by chronic liver diseases. Liver cirrhosis is a risk factor of HCC and 90% of patients with HCC are associated with liver cirrhosis. Aim of the Work: To evaluate the potential clinical value of serum resistin levels in patients with liver cirrhosis and hepatocellular carcinoma (HCC) before and after treatment and to correlate these levels with metabolic profile in those patients before and after intervention of HCC.
Patients and Methods: This a comparative intervention study was conducted at The Gastroenterology and Hepatology Unit, Department of Internal Medicine, Ain Shams University on 50 Egyptian patients with liver cirrhosis and hepatocellular carcinoma before and after treatment during the period of January 2017 and July 2017.
Results: Serum resistin levels are higher in patients with HCC than patients with cirrhosis and serum resistin levels are lower in patients with HCC after treatment than before their treatment.
Conclusion: Patients with HCC have significant higher serum resistin levels than patients with cirrhosis with significant reduction in its level after intervention for HCC that consider resistin as a possible marker in follow up the therapeutic response in HCC patients.
Recommendations: Further studies are needed to evaluate relationship between resistin and hepatic cirrhosis and its pathogenesis in HCC development